Lipid-Lowering Drugs and Pulmonary Vascular Disease: A Mendelian Randomization Study

Area of Science:

• Cardiovascular Genetics
• Pulmonary Medicine
• Pharmacogenomics

Background:

• The role of lipid-lowering drugs in treating pulmonary vascular diseases is not well-established.
• Existing evidence is limited, necessitating further investigation into causal relationships.

Purpose of the Study:

• To investigate the causal effects of specific lipid-lowering drug targets (APOB, CETP, HMGCR, NPC1L1, PCSK9) on pulmonary arterial hypertension (PAH), pulmonary embolism (PE), and pulmonary heart disease (PHD).
• To leverage a Mendelian randomization (MR) approach using genetic data to infer these causal links.

Main Methods:

• Utilized summary statistics from genome-wide association studies (GWAS) for low-density lipoprotein cholesterol (LDL-C) and pulmonary vascular disease outcomes.
• Selected single-nucleotide polymorphisms (SNPs) near drug target loci as genetic proxies for lipid-lowering drug effects.
• Employed inverse variance weighted (IVW) and MR-Egger methods for causal effect estimation, using data from FinnGen and UK Biobank.

Main Results:

• LDL-C mediated by NPC1L1 and PCSK9 was significantly associated with an increased risk of PAH.
• LDL-C mediated by APOB showed a significant association with a decreased risk of PE and PHD in both FinnGen and UK Biobank cohorts.
• No significant associations were found for LDL-C mediated by CETP or HMGCR with PAH, PE, or PHD risks.

Conclusions:

• This MR study provides evidence for the causal effects of NPC1L1 and PCSK9 inhibition, suggesting a potential increase in PAH risk.
• APOB inhibition appears to have a protective effect, potentially reducing the risk of PE and PHD.
• Findings contribute to understanding the complex interplay between lipid metabolism and pulmonary vascular diseases, informing potential therapeutic strategies.